Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Down 67.3% in February

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 14,600 shares, a decrease of 67.3% from the February 13th total of 44,700 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 59,100 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.

Fresenius SE & Co. KGaA Price Performance

FSNUY stock traded up $0.39 during trading on Friday, hitting $11.02. 45,104 shares of the company’s stock traded hands, compared to its average volume of 56,628. Fresenius SE & Co. KGaA has a 52 week low of $6.57 and a 52 week high of $11.16. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36. The business has a fifty day simple moving average of $9.79 and a 200 day simple moving average of $9.33. The stock has a market capitalization of $24.62 billion, a price-to-earnings ratio of 52.48 and a beta of 1.02.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The business had revenue of $6.01 billion for the quarter. As a group, research analysts expect that Fresenius SE & Co. KGaA will post 0.79 EPS for the current fiscal year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.